Results 21 to 30 of about 894,811 (216)

Sex related differences in acute and recurrent pericarditis: A narrative review [PDF]

American Heart Journal Plus
Background: Acute and recurrent pericarditis represent significant clinical challenges, with growing evidence suggesting important sex-related differences in their presentation, etiology, and course.
Nouf Alanazi
doaj   +2 more sources

IL-1 Pathway Inhibition in Recurrent Pericarditis Management: Real-World Adoption of Corticosteroid Sparing in RESONANCE. [PDF]

JACC Adv
Background Recurrent pericarditis (RP) guidelines recommend second-line corticosteroids after aspirin/nonsteroidal anti-inflammatory drugs/colchicine, but complications of protracted use underscore the importance of corticosteroid-sparing strategies ...
Cremer PC, Luis SA, Garshick MS, Raisinghani A, Weber B, Winnowski D, Clair J, Parameswaran V, Curtis A, Klein AL, Paolini JF, RESONANCE Study Group.   +11 more
europepmc   +2 more sources

Running into trouble: exercise-exacerbated recurrent pericarditis-a case report. [PDF]

Eur Heart J Case Rep
Background Recurrent pericarditis is an inflammatory condition characterized by symptom recurrence after an initial episode. Exercise-induced flares are underrecognized.
Calcagno T, Ikram J, Berglund F, Klein A.   +3 more
europepmc   +2 more sources

Duration of Disease and Long-Term Outcomes in Patients With Difficult-To-Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti-Inflammatory Drugs, Colchicine, Corticosteroids, and Anti-Interleukin-1 Agents. [PDF]

ACR Open Rheumatol
We aimed to investigate the remission rate and disease duration in idiopathic or post–cardiac injury pericarditis and risk factors for disease duration and anti–interleukin‐1 (IL‐1) agent discontinuation.
Ceriani E, Agozzino F, Berra S, Gidaro A, Bindi P, Pavarani A, Macchi S, Vena L, Moda F, Sicignano LL, Murace CA, Gerardino L, Verrecchia E, De Carlini CC, Maestroni S, Marinaro G, Bizzi E, Brucato A, Imazio M.   +18 more
europepmc   +2 more sources

Rilonacept in Refractory Immune Checkpoint Inhibitor-Induced Recurrent Pericarditis: A Potential Treatment Option. [PDF]

JACC Case Rep
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with rare immune-related adverse events, particularly cardiotoxicity.
Patel H, Thangjui S, Watson H, Balla S.
europepmc   +2 more sources

Recurrent pericarditis in a patient with Bardet–Biedl syndrome: A case report [PDF]

Frontiers in Pediatrics, 2022
Bardet–Biedl syndrome is a rare autosomal recessive disorder characterized by rod-cone dystrophy, renal dysfunction, obesity, learning difficulties, hypogonadism, polydactyl, and many other minor features that can affect the cardiovascular, locomotive ...
Angela Mauro, Francesca Casini, Emanuele Chittano Congedo, Sara L’assainato, Francesca Pinto, Valentina Ansuini, Ruggiero Mascolo, Alice Pedroli, Luca Bernardo   +8 more
doaj   +2 more sources

Recurrent Pericarditis and Paradigm Shift in Cardiovascular Imaging and Targeted Therapeutics. [PDF]

JACC Adv
Recurrent pericarditis poses a significant challenge to patients and clinicians given its high morbidity and health care burden. Since the last iteration of European Society of Cardiology Guidelines in 2015, further insights have been gained into the ...
Karmali R, Kafil TS, Bayat A, Honnekeri B, Badwan O, Berglund F, Cremer P, Klein AL.   +7 more
europepmc   +2 more sources

Genetic variants in patients with recurrent pericarditis. [PDF]

J Cardiovasc Med (Hagerstown)
Aims Presence of family cases and multiple recurrences of pericarditis suggest the existence of a possible genetic background in at least 10% of cases.
Imazio M, Faletra F, Zucco J, Mio C, Carraro M, Gava AM, De Biasio M, Damante G, Collini V.   +8 more
europepmc   +2 more sources

Anakinra-Dependent Recurrent Pericarditis: The Role of the R202Q Variant of the MEFV Gene. [PDF]

J Clin Med
Background: the role of the R202Q (c.605G>A, p.Arg202Gln) missense variant of the MEFV gene has been debated as either a benign polymorphism or a potentially pathogenic mutation.
Andreis A, Dossi FC, De Ferrari GM, Alunni G, Imazio M.   +4 more
europepmc   +2 more sources

Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis. [PDF]

Open Heart
Aim Anakinra, an anti IL-1 agent targeting IL-1 alfa and beta, is available for the treatment of recurrent pericarditis in cases with corticosteroid dependence and colchicine resistance after failure of conventional therapies.
Collini V, Andreis A, De Biasio M, De Martino M, Isola M, Croatto N, Lepre V, Cantarini L, Merlo M, Sinagra G, Abbate A, Lazaros G, Brucato A, Klein AL, Imazio M.   +14 more
europepmc   +2 more sources